FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 813 participants.

Also called NCT03276143

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 813 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03276143
  • EudraCT 2016-002681-31
Other papers using this trial's data
  • Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial JAMA, 2020-01-14 DOI, PubMed 31935028, PMC6990695 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Bulgaria, Canada, Czechia, Greece, Israel, Latvia, Lithuania, Poland, Portugal, Russia, South Africa, Spain, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03276143. Randomized; quadruple masking; primary purpose prevention. Start 2017-09-21 (actual); primary completion 2018-08-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty
Acronym
FOXTROT
Condition
Knee Arthroplasty, Total
Intervention (Drug)
Enoxaparin
Intervention (Drug)
Apixaban
Intervention (Drug)
BAY1213790
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct03276143
Content hash
8c29bbbe6f1147633922450b20402b5ec8abee82a1f4a4dd9f7eea37ea5a57ee